Somatostatin receptor tissue distribution in lung neuroendocrine tumours: a clinicopathologic and immunohistochemical study of 218 'clinically aggressive' cases.
about
Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoidsA challenging case of an ectopic cushing syndrome.Somatostatin Receptors in Lung Cancer: From Function to Molecular Imaging and TherapeuticsClinical analysis of 50 Eastern Asian patients with primary pulmonary large-cell neuroendocrine carcinoma.The Diagnosis and Treatment of Bronchopulmonary Carcinoid68Ga-DOTATATE PET/CT imaging of indeterminate pulmonary nodules and lung cancer.Correlation between Semi-Quantitative (18)F-FDG PET/CT Parameters and Ki-67 Expression in Small Cell Lung CancerNeuroendocrine tumors of the lungSomatostatin receptor biology in neuroendocrine and pituitary tumours: part 2--clinical implicationsThe molecular pathogenesis and management of bronchial carcinoids.The pathological diagnosis of neuroendocrine tumors: common questions and tentative answers.Unraveling tumor grading and genomic landscape in lung neuroendocrine tumors.Therapeutic biomarkers in lung neuroendocrine neoplasia.The expanding role of somatostatin analogs in gastroenteropancreatic and lung neuroendocrine tumors.Diagnosis and treatment of bronchopulmonary neuroendocrine tumours: State of the art.Effects of the single and combined treatment with dopamine agonist, somatostatin analog and mTOR inhibitors in a human lung carcinoid cell line: an in vitro study.Synthesis, drug release, and biological evaluation of new anticancer drug-bioconjugates containing somatostatin backbone cyclic analog as a targeting moiety.Algorithmic approach to neuroendocrine tumors in targeted biopsies: Practical applications of immunohistochemical markers.Exploiting cancer's phenotypic guise against itself: targeting ectopically expressed peptide G-protein coupled receptors for lung cancer therapy.Association Between Somatostatin Receptor Expression and Clinical Outcomes in Neuroendocrine Tumors.Lung neuroendocrine tumours: deep sequencing of the four World Health Organization histotypes reveals chromatin-remodelling genes as major players and a prognostic role for TERT, RB1, MEN1 and KMT2D.Carcinoid tumor with localized bronchiectasis.Characterization of neuroendocrine tumors of the pancreas by real-time quantitative polymerase chain reaction. A methodological approach.Somatostatin receptor scintigraphy with 111In-octreotide in pulmonary carcinoid tumours correlated with pathological and 18FDG PET/CT findings.Somatostatin receptor expression related to TP53 and RB1 alterations in pancreatic and extrapancreatic neuroendocrine neoplasms with a Ki67-index above 20.Peptide receptor radionuclide therapy with (177)Lu-DOTATATE in advanced bronchial carcinoids: prognostic role of thyroid transcription factor 1 and (18)F-FDG PET.[Pulmonary neuroendocrine tumors in the new WHO 2015 classification: Start of breaking new grounds?].Gene expression of somatostatin receptor subtypes SSTR2a, SSTR3 and SSTR5 in peripheral blood of neuroendocrine lung cancer affected patients.Advances on systemic treatment for lung neuroendocrine neoplasms.International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature
P2860
Q26996521-D4EC6150-9D29-4E00-8CB4-563A5A352DE6Q34562501-521A1A25-AB97-4696-901C-B3BA540CBD34Q35057473-A4C0F8A9-3133-434A-A086-173B3E9EC11DQ35679386-B18592FD-D6F5-4D8A-A0BE-8B2475426AF0Q35916386-B4A60A64-D88E-45AF-94CF-13C1C66A9EFAQ36275598-4FA4490E-333B-492F-A3E6-4045ED63DC49Q36604990-ECF22FF5-AD98-43A4-ABEA-4CC99DD292CAQ37017067-38920217-1B65-43C5-AED9-8ED4354E1266Q37772579-978572C1-F632-4A59-85F7-28BE7D309C17Q37833109-8F7A90EA-520C-4E80-8AFC-F123C84B0A32Q37846130-760AEBD5-478B-4AE1-8340-82A68A2B8A20Q38207553-948CA8ED-DB5C-40DA-B868-B7BBA5143018Q38253997-EC84AF63-26D6-4179-9BDC-350251CDA2FDQ38441413-939DC9A2-5698-490C-876F-7C13A3374D56Q38557054-17FA50A3-2127-4F69-B66D-B4E4A0A96156Q38743093-40204A6D-4332-4FC6-BF89-A9848EE4E1F4Q38865705-B063B7A7-06A2-486A-ABF6-C53D6C673927Q38928817-D7E9726B-015C-45FF-8D90-533036ABB89CQ39378866-004A7EE1-63A6-41AE-9148-4DF7A0B7A379Q40540183-327DC220-6F74-48CD-8FB4-A3B578370D0EQ41981114-7482552E-0BBE-4F1C-92E3-813C04DD7ED3Q42859026-BF44BD5A-E5A7-4B13-8E9D-24B7582F534DQ44715004-3F083CC4-D220-40AA-9D05-E3AAEC473C08Q47378726-7B4B31BB-E27B-412C-9131-783DF550AD84Q48088751-960D8CB7-D2D8-4CA2-9FB8-6A3C6CFBBE97Q52987702-2493A0DC-A598-4A48-84EF-981827608CB8Q53512514-94263378-0691-435D-8175-636958A660CAQ54377238-1AE1BD1D-C36C-4975-A748-D769B0B4FFFDQ55375491-505DC535-6CEA-4216-ACA2-B9DA5B142B33Q57144951-5556B191-FDCD-4894-8D14-D7256C2870B3
P2860
Somatostatin receptor tissue distribution in lung neuroendocrine tumours: a clinicopathologic and immunohistochemical study of 218 'clinically aggressive' cases.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Somatostatin receptor tissue d ...... 'clinically aggressive' cases.
@en
Somatostatin receptor tissue d ...... 'clinically aggressive' cases.
@nl
type
label
Somatostatin receptor tissue d ...... 'clinically aggressive' cases.
@en
Somatostatin receptor tissue d ...... 'clinically aggressive' cases.
@nl
prefLabel
Somatostatin receptor tissue d ...... 'clinically aggressive' cases.
@en
Somatostatin receptor tissue d ...... 'clinically aggressive' cases.
@nl
P2093
P2860
P356
P1433
P1476
Somatostatin receptor tissue d ...... 'clinically aggressive' cases
@en
P2093
V Tavaglione
P2860
P304
P356
10.1093/ANNONC/MDP334
P577
2009-09-16T00:00:00Z